shorthound, excellent info. also I went back and read dr doody's papers and old PR's last night and learned quite a bit. From what I read, it does appear that the Invocell will be agood choice for the vast majority of patients, and in a market that will exceed 20B, even a small percentage of that market will be very significant. All IMHO, appreciate your inputs.
News 
Market Data 
Discover 
AI
